December 2022 - BioMedWire (BMW)

ThursdayDec 29, 2022 11:49 am

Research Discovers Bidirectional Link Between Lower-Back Pain, Insomnia

Most people experience lower-back pain at some point in their lives, be it as a result of injury, chronic back issues, pregnancy, periods and other underlying physiological issues. Prior studies have found links between lower-back pain and a range of psychological and social factors, including body weight, gender, mood disorders and smoking habits. Despite this, identifying the origin of lower back pain is still challenging. Now, a new study has linked lower-back pain to sleep disturbances and insomnia. Insomnia is a common sleep disorder that makes it hard for individuals to stay asleep or fall asleep. The study, which was…

WednesdayDec 28, 2022 11:26 am

New Research Shows Brain Stimulation Improves Reading Ability of Macular Degeneration Patients

Macular degenerative disease is one of the leading causes of vision loss in older adults across the world. It is characterized by loss of central vision as part of the inner layers of the retina that facilitate clear vision steadily break down. Around 20 million adults in America are estimated to live with some kind of age-related macular degeneration (AMD), with adults aged 75 and above having a 30% risk of developing the disease. The condition makes it extremely frustrating and difficult to read, forcing many AMD patients to give up on reading altogether. However, a study from the University…

WednesdayDec 28, 2022 11:15 am

Aditxt Inc. (NASDAQ: ADTX) Announces Goal of First-in-Human Trials for Drug Candidate ADI(TM)-100 with a Focus on Psoriasis

Dr. Joachim-Friedrich Kapp is leading Aditxt’s ADI(TM) immune modulation technology development toward clinical trials The global psoriasis therapeutics market was valued at $22.9 billion in 2021 and is projected to reach $55.8 billion by 2031, growing at a CAGR of 9.3% The primary goal of the first-in-human clinical trial is to demonstrate the safety of Aditxt’s ADI(TM) technology; in addition, the trial has been designed to evaluate the ability of ADI(TM) to restore immune tolerance Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, is focused on mapping…

WednesdayDec 28, 2022 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Continues to See Growth in Patient Enrollment for Brain Cancer Drug Candidate Global Clinical Trial

CNS Pharmaceuticals is conducting a potentially pivotal clinical trial in the United States and Europe to establish the effectiveness of a drug candidate for combating incurable glioblastoma (“GBM”) brain cancers CNS’s flagship drug candidate is called Berubicin, a product initially developed by another company with encouraging small-population results in 2006, and CNS is expanding the testing with expectations of eventually delivering an innovative new GBM treatment to market The company aims to enroll more than 200 patients in its global Berubicin trial on a 2:1 randomization schema comparing Berubicin-treated patients to those receiving second-line standard of care chemotherapy agent lomustine…

TuesdayDec 27, 2022 1:52 pm

Machine Learning Effort Enables Large-Scale Cancer Study to Improve Boundary Detection

Scientists at the University of Pennsylvania School of Medicine and Intel Corp. carried out a large-scale international machine learning effort to collect knowledge from brain scans of more than 6,000 patients with glioblastoma at various sites globally. Their objective was to develop a model that could improve identification and prediction of boundaries in different tumor subcompartments. Spyridon Bakas, an assistant professor at Penn Medicine, stated that the study had the single biggest and most-diverse glioblastoma patient dataset ever considered in the literature, noting that this was facilitated through federated learning. Bakas also noted that the machine learning models became more…

TuesdayDec 27, 2022 10:30 am

Advisory Firm Appointment Underscores MetAlert, Inc. (MLRT) Strategy Amid Growth Stage and New Patient Location-tracking Technology Rollout

Pioneering GPS-enabled location device developer MetAlert is building on two decades of experience with new products designed to broaden its suite of technology for remote patient monitoring (“RPM”) in an unobtrusive manner plus monitoring seniors for falls MetAlert recently announced that it has engaged the financial strategy advisory firm Joseph Gunnar & Co., LLC to help direct its decisions ranging from acquisitions to potential up listing on a national exchange The company’s products include its flagship patented shoe insole device enabled with GPS, Bluetooth, and Wi-Fi functionality for tracking seniors or people with autism prone to wandering and getting lost,…

ThursdayDec 22, 2022 12:42 pm

Research Suggests That Vegetarian Diets Decrease Prostate Cancer Risk

Prostate cancer is the most common cancer in American men, affecting an estimated 3.2 million men in the country. While we don’t know exactly what causes prostate cancer, risk factors for the disease include age, family history, diet, obesity and ethnicity. Research has indicated that there may be some association between obesity and diet and the prevalence of prostate cancer. These past studies suggest that regular exercise and a balanced diet may help to reduce the risk of prostate cancer. Urologist Dr. Stephen Freedland, director of Cedars-Sinai Medical Center’s Center for Integrated Research in Cancer and Lifestyle, recently conducted a…

ThursdayDec 22, 2022 12:00 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Updates of Recent Key Events and Plans for Calendar 2023; Announces Public Offering to Raise Funding for Operations

CNS Pharmaceuticals is a biopharmaceutical company that focuses on developing novel treatments for primary and metastatic cancers in the brain and central nervous system The company is currently evaluating the efficacy of Berubicin, a novel anthracycline that appears to cross the blood-brain barrier, in a potentially pivotal Phase 2 trial involving patients with recurrent glioblastoma multiforme (“GBM”) CEO John Climaco recently participated in the Virtual Investor “Ask the CEO” Event in which he provided an update on recent key events and plans for the future in addition to allaying the investors’ concerns regarding the recent reverse stock split CNS Pharmaceuticals…

WednesdayDec 21, 2022 10:55 am

Experts Push for More Studies into Link Between Asthma, Female Sex Hormones

Asthma is a common condition that causes an individual’s airways to swell and narrow, resulting in breathing difficulties, coughing and breathlessness. During childhood, the disease is more prevalent and severe in boys. Following puberty, however, asthma becomes more common and severe in women. Women have a heightened risk of developing this condition because female sex hormones can worsen symptoms of asthma, much like dust, pollen and air pollution does. The hormones may even trigger an asthma attack. It is common knowledge that women who have asthma are at risk of possibly fatal asthma attacks every month and experience worse symptoms…

WednesdayDec 21, 2022 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) CEO Featured Guest on Big Biz Show, Talks ‘Breakthrough’ Heart-Attack Detection Technology

BEAT has developed technology that collects data to synthesize a 12-lead 3D vector electrocardiogram (“VECG”) The device provides physicians with a 12-lead ECG associated with chest pain compared to a baseline ECG for the patient This key data enables physicians to assess whether symptoms may be the result of a heart attack HeartBeam’s (NASDAQ: BEAT) small, portable, easy-to-use heart-attack detection solution was the focus of a recent Big Biz Show episode; the Big Biz Show features fast-talking, hard-hitting discussions on business and finance. During the interview, Big Biz Show host Bob “Sully” Sullivan chatted with HeartBeam founder and CEO Branislav…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

Month: December 2022

Research Discovers Bidirectional Link Between Lower-Back Pain, Insomnia

New Research Shows Brain Stimulation Improves Reading Ability of Macular Degeneration Patients

Aditxt Inc. (NASDAQ: ADTX) Announces Goal of First-in-Human Trials for Drug Candidate ADI(TM)-100 with a Focus on Psoriasis

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Continues to See Growth in Patient Enrollment for Brain Cancer Drug Candidate Global Clinical Trial

Machine Learning Effort Enables Large-Scale Cancer Study to Improve Boundary Detection

Advisory Firm Appointment Underscores MetAlert, Inc. (MLRT) Strategy Amid Growth Stage and New Patient Location-tracking Technology Rollout

Research Suggests That Vegetarian Diets Decrease Prostate Cancer Risk

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Updates of Recent Key Events and Plans for Calendar 2023; Announces Public Offering to Raise Funding for Operations

Experts Push for More Studies into Link Between Asthma, Female Sex Hormones

HeartBeam Inc. (NASDAQ: BEAT) CEO Featured Guest on Big Biz Show, Talks ‘Breakthrough’ Heart-Attack Detection Technology

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search